Buy this biotech stock on weakness: Barclays

June 25, 2026 3:00 AM

Barclays reiterated an "overweight" rating on this Biotech company and raised its conviction in the drugmaker's Phase 3 myositis trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found